The Emergence of Cancer Vaccines: Reframing Value Demonstration, Pricing, and Access
The Emergence of Cancer Vaccines: Reframing Value Demonstration, Pricing, and Access
Published on PharmExec
Cancer vaccination has evolved significantly over the past few decades, beginning with the FDA approval of Bacillus Calmette–Guérin (BCG) for bladder cancer in 1990, followed by the preventative HPV vaccine Gardasil in 2006 and the first therapeutic cancer vaccine, Provenge, in 2010. While progress was steady, the COVID-19 pandemic marked a turning point by validating mRNA technology at global scale and accelerating investment in vaccine research and manufacturing infrastructure.
In this article, published on Pharmexec, Anaïs Frappé, and Michelle Wang, examine recent developments in cancer vaccines and outline a pricing & access framework for manufacturers to successfully commercialise these vaccines.
About the authors
Anaïs Frappé is a Principal at Windrose Consulting Group in London. She has over 15 years of healthcare consulting experience in pricing & access, commercial, private equity, and org. strategy. Michelle Wang is an Analyst at Windrose Consulting Group in Philadelphia.
Please get in touch if you would like to discuss.